Novo Nordisk (NYSE:NVO) announced new phase 3b trial (DUAL VII) results with Xultophy® (IDegLira). Xultophy®is a once-daily, single injection fixed combination of a …
When I read all these articles about investing strategies and look at the moves from big gurus, I see Europe as a dominant …
